HomeCompareMDT vs ARES

MDT vs ARES: Dividend Comparison 2026

MDT yields 3.31% · ARES yields 4.37%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARES wins by $2929.58M in total portfolio value
10 years
MDT
MDT
● Live price
3.31%
Share price
$85.74
Annual div
$2.84
5Y div CAGR
29.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.3K
Annual income
$9,789.15
Full MDT calculator →
ARES
ARES
● Live price
4.37%
Share price
$107.66
Annual div
$4.71
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2929.64M
Annual income
$2,806,406,662.94
Full ARES calculator →

Portfolio growth — MDT vs ARES

📍 ARES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDTARES
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDT + ARES cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDT pays
ARES pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDT
Annual income on $10K today (after 15% tax)
$281.55/yr
After 10yr DRIP, annual income (after tax)
$8,320.78/yr
ARES
Annual income on $10K today (after 15% tax)
$371.87/yr
After 10yr DRIP, annual income (after tax)
$2,385,445,663.50/yr
At 15% tax rate, ARES beats the other by $2,385,437,342.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDT + ARES for your $10,000?

MDT: 50%ARES: 50%
100% ARES50/50100% MDT
Portfolio after 10yr
$1464.85M
Annual income
$1,403,208,226.05/yr
Blended yield
95.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MDT right now

MDT
Analyst Ratings
1
Strong
26
Buy
22
Hold
Consensus: Buy
Price Target
$111.45
+30.0% upside vs current
Range: $100.00 — $120.00
Altman Z
2.9
Piotroski
7/9
ARES
Analyst Ratings
1
Strong
15
Buy
5
Hold
Consensus: Buy
Price Target
$179.25
+66.5% upside vs current
Range: $148.00 — $215.00
Altman Z
1.5
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDT buys
0
ARES buys
0
No recent congressional trades found for MDT or ARES in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDTARES
Forward yield3.31%4.37%
Annual dividend / share$2.84$4.71
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR29.3%100%
Portfolio after 10y$54.3K$2929.64M
Annual income after 10y$9,789.15$2,806,406,662.94
Total dividends collected$29.9K$2920.90M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$111.45$179.25

Year-by-year: MDT vs ARES ($10,000, DRIP)

YearMDT PortfolioMDT Income/yrARES PortfolioARES Income/yrGap
1← crossover$11,128$428.29$11,575$874.98$447.00ARES
2$12,483$575.94$14,278$1,893.05$1.8KARES
3$14,138$780.71$19,643$4,364.80$5.5KARES
4$16,196$1,068.46$32,241$11,223.63$16.0KARES
5$18,809$1,479.09$68,932$34,434.38$50.1KARES
6$22,201$2,075.70$211,368$137,610.38$189.2KARES
7$26,716$2,960.69$1,014,866$788,702.55$988.1KARES
8$32,891$4,305.30$8,164,206$7,078,299.39$8.13MARES
9$41,599$6,405.16$115,169,668$106,433,966.79$115.13MARES
10$54,300$9,789.15$2,929,638,207$2,806,406,662.94$2929.58MARES

MDT vs ARES: Complete Analysis 2026

MDTHealthcare

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Full MDT Calculator →

ARESStock

Ares Management Corporation operates as an alternative asset manager in the United States, Europe, and Asia. The company's Tradable Credit Group segment manages various types of investment funds, such as commingled and separately managed accounts for institutional investors, and publicly traded vehicles and sub-advised funds for retail investors in the tradable and non-investment grade corporate credit markets. Its Direct Lending Group segment provides financing solutions to small-to-medium sized companies. The company's Private Equity Group segment focuses on majority or shared-control investments primarily in under-capitalized companies. Its Real Estate Group segment invests in new developments and the repositioning of assets, with a focus on control or majority-control investments; and originates and invests in a range of self-originated financing opportunities for middle-market owners and operators of commercial real estate. The firm was previously known as Ares Management, L.P. Ares Management Corporation was founded in 1997 and is headquartered in Los Angeles, California with additional offices in the United States, Europe and Asia. Ares Management GP LLC is the general partner of the company.

Full ARES Calculator →
📬

Get this MDT vs ARES comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDT vs SCHDMDT vs JEPIMDT vs OMDT vs KOMDT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.